GALNT4 predicts survival in patients with ccRCC
As reported in the Journal of Urology, N-acetylgalactosaminyltransferase 4 (GALNT4) levels are decreased in tumor specimens from patients with clear cell renal cell carcinoma (ccRCC; n=104) compared to peritumoral specimens. Decreased expression of GALNT4 is associated with poor OS (OR=3.08) and RFS (OR=2.17). Further, GALNT4 is negatively correlated with tumor size, necrosis, and TNM stage.
3-month PSA is a predictor of BCR-free survival after radical prostatectomy
As reported in the International Journal of Clinical Oncology, the 5-year biochemical recurrence (BCR)-free survival rate is significantly higher in patients with a 3-month PSA level < 0.010 ng/ml compared to patients with a 3-month PSA level between 0.010 and 100 ng/ml (92.6% vs. 57.4%). Amongst 174 men who underwent radical prostatectomy for clinically localized prostate cancer, 18.4% had a BCR and the median time to BCR was 16 months.
High expression of MUC1 + HER3 is associated with favorable outcome in bladder cancer patients
As reported in BJU International, elevated co-expression of MUC1 + HER3 was associated with improved survival in patients with bladder cancer. MUC1 alone, or elevated MUC1 + non-elevated HER3, had no prognostic value. Moreover, MUC1 was not predictive of survival, tumor stage, or tumor grade.